MedTrace Logo

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

NCT02433678 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-10-30

Study results available
· View outcomes & findings →

Summary

This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with dapagliflozin.

Conditions

Interventions

DRUG

dapagliflozin

SGLT-2 inhibitor for the treatment of type 2 diabetes

DRUG

Placebo

Sponsors & Collaborators

  • Kaleida Health

    collaborator OTHER

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Paresh Dandona, MD, PhD · University at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-03-31
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02433678 on ClinicalTrials.gov